| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e61cfb51fa2b44c437821e74916283f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 |
| filingDate |
1995-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb69d461612702a6231434da2368601a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2b55d0379f72c35a1ad492bb6b3e81e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80bfb92abeab3e9a4cdcf7a0314fd18f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6c8af8d6bfb580fb294a2ac6e0fd554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0117f57d16fc05ead07f7b358cdfd77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75892e5b121a245f4219e826264020a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_994f3d22bf2f828fb70d72ef318eec8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83c3d2bdbc43236a560653f2b3a474f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed504d9e8a658d76693817317f279477 |
| publicationDate |
1997-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0782584-A1 |
| titleOfInvention |
Il-1 receptor antagonists with enhanced inhibitory activity |
| abstract |
DNA molecules that code for IL-1 antagonists with improved biological activity are described. DNA molecules coding for improved IL-1 antagonists inserted into expression vectors and host cells transformed with the said vectors containing the DNA coding for improved IL-1 antagonists and a method for the production of improved IL-1 antagonists in essentially pure form are also described. Preparations that can be injected or can be administered by some other route, consisting of a pharmaceutical preparation of the said mutants, are particularly useful as drugs in the field of therapy. |
| priorityDate |
1994-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |